Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014

#	Paper	IF	Citations
292	Primary central nervous system tumor treatment and survival in the United States, 2004-2015. **2019**, 144, 179-191		19
291	The effect of race on the prognosis of the glioblastoma patient: a brief review. **2019**, 41, 967-971		14
290	Barriers to accrual and enrollment in brain tumor trials. *Neuro-Oncology*, **2019**, 21, 1100-1117	1	25
289	AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy. **2019**, 108, 3684-3694		18
288	Racial differences in brain cancer characteristics and survival: an analysis of SEER data. **2019**, 30, 1283-1291		4
287	Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells. **2019**, 2019, 2710693		18
286	A man with weak limbs. **2019**, 367, l6233		
285	Prognostic Implications of the Complement Protein C1q in Gliomas. **2019**, 10, 2366		20
284	Long non-coding RNA LINC00174 promotes glycolysis and tumor progression by regulating miR-152-3p/SLC2A1 axis in glioma. **2019**, 38, 395		43
283	Epstein-Barr virus infection in gliomas. **2019**, 67, 129-133		8
282	Race influences survival in glioblastoma patients with KPS 80 and associates with genetic markers of retinoic acid metabolism. **2019**, 142, 375-384		8
281	Differentiation antagonizing non-protein coding RNA modulates the proliferation, migration, and angiogenesis of glioma cells by targeting the miR-216a/LGR5 axis and the PI3K/AKT signaling pathway. **2019**, 12, 2439-2449		13
280	Glioma incidence and survival variations by county-level socioeconomic measures. **2019**, 125, 3390-3400		36
279	Genetic and molecular epidemiology of adult diffuse glioma. **2019**, 15, 405-417		205
278	Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations. **2019**, 9, 7442		18
277	Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database. **2019**, 143, 349-357		4
276	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. **2019**, 1, vdz036		2

275	18F-Fluorocholine PET/CT in the Prediction of Molecular Subtypes and Prognosis for Gliomas. **2019**, 44, e548-e558		8
274	Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival. **2019**, 142, 27-38		7
273	Disparities along the glioblastoma clinical trials landscape. *Neuro-Oncology*, **2019**, 21, 285-286	1	2
272	Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden. **2019**, 141, 139-149		5
271	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. **2020**, 146, 739-748		14
270	Coexistence of multiple sclerosis and brain tumours: Case report and review. **2020**, 19, 100585		2
269	Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. **2020**, 7, 299-305		1
268	Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. **2020**, 7, 306-312		7
267	Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies. **2020**, 2, vdaa085		0
266	Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis. **2020**, 10, 1631		8
265	Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review. **2020**, 22, 120		4
264	European genetic ancestry associated with risk of childhood ependymoma. *Neuro-Oncology*, **2020**, 22, 1637-1646	1	5
263	Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma. **2020**, 39, 137		21
262	RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma. **2020**, 87, 106707		8
261	Community economic factors influence outcomes for patients with primary malignant glioma. **2020**, 7, 453-460		2
260	Longer-term (2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. **2020**, 10, 11622		60
259	Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment. **2020**, 22, 93		4
258	Research Objectives, Statistical Analyses and Interpretation of Health-Related Quality of Life Data in Glioma Research: A Systematic Review. *Cancers*, **2020**, 12,	6.6	1

257	Evaluation of a tumor electric field treatment system in a rat model of glioma. **2020**, 26, 1168-1177		3
256	Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. **2020**, 149, 55-64		8
255	Recent Advancements in Liposome-Targeting Strategies for the Treatment of Gliomas: A Systematic Review.. **2020**, 3, 5500-5528		12
254	Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016. **2020**, 7, 549-558		1
253	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. *Neuro-Oncology*, **2020**, 22, iv1-iv96	1	429
252	Subtraction Maps Derived from Longitudinal Magnetic Resonance Imaging in Patients with Glioma Facilitate Early Detection of Tumor Progression. *Cancers*, **2020**, 12,	6.6	1
251	Pediatric glioma and medulloblastoma risk and population demographics: a Poisson regression analysis. **2020**, 2, vdaa089		2
250	Improving human cancer therapy through the evaluation of pet dogs. **2020**, 20, 727-742		33
249	Salvage Radiation Therapy for Patients With Relapsing Glioblastoma Multiforme and the Role of Slow Fractionation. **2020**, 10, 577443		2
248	LncRNA H19 Promotes Cell Proliferation, Migration, and Angiogenesis of Glioma by Regulating Wnt5a/ECatenin Pathway via Targeting miR-342. **2020**, 1		14
247	Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013. **2020**, 148, 69-79		5
246	PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review. **2020**, 15, 2789-2808		32
245	Incidence and Outcomes of CNS Tumors in Chinese Children: Comparative Analysis With the Surveillance, Epidemiology, and End Results Program. **2020**, 6, 704-721		2
244	Management of glioblastoma: State of the art and future directions. **2020**, 70, 299-312		328
243	Tep1 Regulates Yki Activity in Neural Stem Cells in Glioma Model. **2020**, 8, 306		5
242	The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme. **2020**, 59, 1064-1075		3
241	A systematic review of tumor treating fields therapy for high-grade gliomas. **2020**, 148, 433-443		6
240	Racial/Ethnic Disparities and Survival in Pediatrics with Gliomas Based on the Surveillance, Epidemiology, and End Results Database in the United States. **2020**, 141, e524-e529		2

239   Assessment of the Extent of Resection in Surgery of High-Grade Glioma-Evaluation of Black Blood Sequences for Intraoperative Magnetic Resonance Imaging at 3 Tesla. *Cancers*, **2020**, 12,   6.6   1

238   Overexpression of LncRNA PSMG3-AS1 Distinguishes Glioblastomas from Sarcoidosis. **2020**, 70, 2015-2019   5

237   Lcn2-derived Circular RNA (hsa_circ_0088732) Inhibits Cell Apoptosis and Promotes EMT in Glioma via the miR-661/RAB3D Axis. **2020**, 10, 170   18

236   Associations of lncRNA H19 Polymorphisms at MicroRNA Binding Sites with Glioma Susceptibility and Prognosis. **2020**, 20, 86-96   15

235   Nitidine Chloride Is a Potential Alternative Therapy for Glioma Through Inducing Endoplasmic Reticulum Stress and Alleviating Epithelial-Mesenchymal Transition. **2020**, 19, 1534735419900927   1

234   Comparative epidemiology of gliosarcoma and glioblastoma and the impact of Race on overall survival: A systematic literature review. **2020**, 195, 106054   1

233   A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort. *Neuro-Oncology*, **2020**, 22, 729-731   1   6

232   NCI-CONNECT rare CNS tumor initiative: current progress and anticipated future impact. **2020**, 2, vdaa022   0

231   Sexually dimorphic impact of the iron-regulating gene, , on survival in glioblastoma. **2020**, 2, vdaa001   1

230   Investigation of simian virus 40 (SV40) and human JC, BK, MC, KI, and WU polyomaviruses in glioma. **2020**, 26, 347-357   3

229   Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology. **2020**, 32, 107-117   4

228   Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques. **2020**, 41, 10-20   31

227   Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database. **2020**, 147, 711-720   11

226   Survival among patients with glioma in the US Military Health System: A comparison with patients in the Surveillance, Epidemiology, and End Results program. **2020**, 126, 3053-3060   3

225   Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications. **2020**, 11, 448-461   8

224   Tumour treating fields therapy for glioblastoma: current advances and future directions. **2021**, 124, 697-709   32

223   MR Imaging by 3D T1-weighted black blood sequences may improve delineation of therapy-naive high-grade gliomas. **2021**, 31, 2312-2320   1

222   Static F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. **2021**, 31, 4087-4096   5

221	LINC00473: A novel oncogenic long noncoding RNA in human cancers. **2021**, 236, 4174-4183		5
220	Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. *Neuro-Oncology*, **2021**, 23, 990-998	1	11
219	The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification. *Clinical Cancer Research*, **2021**, 27, 689-703	12.9	43
218	Dietary insulin index and insulin load in relation to glioma: findings from a case-control study. **2021**, 24, 354-362		11
217	Epidemiological Study of Malignant Gliomas in Korea Using Nationwide Dataset from 2007 to 2017. **2021**, 36, e68		3
216	Construction of the National Brain Tumor Registry of China for better management and more efficient use of data: a protocol. **2021**, 11, e040055		0
215	[Epidemiological, clinical, therapeutic and evolutionary features of patients with glioblastoma: series of cases managed in the Department of Hematology-Oncology at the Mohammed VI University Hospital Center in Marrakech in 2016 and 2017]. **2021**, 39, 191		0
214	Brain Tumor Segmentation and Surveillance with Deep Artificial Neural Networks. **2021**, 311-350		0
213	Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017. **2021**, 21, 54		5
212	Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis. **2021**, 21, 81		4
211	Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments. **2020**, 10, 614295		13
210	Epidemiology and Etiology of Glioblastoma. **2021**, 3-19		1
209	Remodeling cancer stemness by collagen/fibronectin the AKT and CDC42 signaling pathway crosstalk in glioma. **2021**, 11, 1991-2005		5
208	LncRNA H19: A novel oncogene in multiple cancers. **2021**, 17, 3188-3208		6
207	Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma. **2020**, 10, 612385		4
206	Silencing of lncRNA LBX2-AS1 suppresses glioma cell proliferation and metastasis through the Akt/GSK3 pathway in vitro. **2021**, 53, 446-453		2
205	GASC1 promotes glioma progression by enhancing NOTCH1 signaling. **2021**, 23,		2
204	Postacute Cognitive Rehabilitation for Adult Brain Tumor Patients. **2021**, 89, 945-953		5

203	Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma. *Cancers*, **2021**, 13,	6.6	3
202	Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy. **2021**, 13, 1159-1168		5
201	Kiaa0101 serves as a prognostic marker and promotes invasion by regulating p38/snail1 pathway in glioma. **2021**, 9, 260		1
200	Small-Molecule HSP27 Inhibitor Abolishes Androgen Receptors in Glioblastoma. **2021**, 64, 1570-1583		3
199	RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma. **2021**, 11, 632934		9
198	Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. **2021**, 68, e28970		2
197	Upregulation of circ-ASPH contributes to glioma cell proliferation and aggressiveness by targeting the miR-599/AR/SOCS2-AS1 signaling pathway. **2021**, 21, 388		3
196	Pediatric Brain Tumors: Descriptive Epidemiology, Risk Factors, and Future Directions. **2021**, 30, 813-821		6
195	A machine learning-based survival prediction model of high grade glioma by integration of clinical and dose-volume histogram parameters. **2021**, 10, 2774-2786		1
194	A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. **2021**, 15, 589906		1
193	Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. **2021**, 152, 603-615		4
192	NPC2 as a Prognostic Biomarker for Glioblastoma Based on Integrated Bioinformatics Analysis and Cytological Experiments. **2021**, 12, 611442		3
191	Exploring Radiologic Criteria for Glioma Grade Classification on the BraTS Dataset. **2021**,		3
190	Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.. **2021**, 11, 497-505		0
189	AGAP2-AS1 May Promote the Occurrence and Development of Glioblastoma by Sponging miR-9-5p: Evidence From a ceRNA Network. **2021**, 11, 607989		3
188	CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing Transcription. **2021**, 11, 638802		2
187	Competing risk model to determine the prognostic factors and treatment strategies for elderly patients with glioblastoma. **2021**, 11, 9321		2
186	Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas. **2021**, 100, e25603		1

| 185 | High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas. *Translational Oncology*, **2021**, 14, 101038 | 4.9 | 0 |

| 184 | High Level of METTL7B Indicates Poor Prognosis of Patients and Is Related to Immunity in Glioma. **2021**, 11, 650534 | 5 |

| 183 | Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. **2021**, 149, e894-e912 | 2 |

| 182 | Detection of metabolic change in glioblastoma cells after radiotherapy using hyperpolarized C-MRI. **2021**, 34, e4514 | 3 |

| 181 | Novel insights for lncRNA MAGI2-AS3 in solid tumors. **2021**, 137, 111429 | 5 |

| 180 | Role of Extracellular Vesicles in Glioma Progression: Deciphering Cellular Biological Processes to Clinical Applications. **2021**, 21, 696-704 | 5 |

| 179 | LDL receptors and their role in targeted therapy for glioma: a review. **2021**, 26, 1212-1225 | 2 |

| 178 | SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. **2021**, 34, 1810-1819 | 1 |

| 177 | Stem cells for the treatment of glioblastoma: a 20-year perspective. **2021**, 10, CNS73 | 1 |

| 176 | Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems. **2021**, 275, 119368 | 25 |

| 175 | Epidemiology and Survival of Patients With Brainstem Gliomas: A Population-Based Study Using the SEER Database. **2021**, 11, 692097 | 2 |

| 174 | Mechanisms of Invasion in Glioblastoma: Extracellular Matrix, Ca Signaling, and Glutamate. **2021**, 15, 663092 | 3 |

| 173 | Neurocytological Advances in the Treatment of Glioblastoma Multiforme. *Cureus*, **2021**, 13, e16301 | 1.2 | 0 |

| 172 | Correlation of natural language assessment results with health-related quality of life in adult glioma patients. **2021**, 1-7 | 0 |

| 171 | Sonodynamic therapy for gliomas. **2021**, 1 | 2 |

| 170 | Development and Validation of a Long-Term 3D Glioblastoma Cell Culture in Alginate Microfibers as a Novel Bio-Mimicking Model System for Preclinical Drug Testing. **2021**, 11, | 3 |

| 169 | A Drosophila RNAi screen reveals conserved glioblastoma-related adhesion genes that regulate collective cell migration. |

| 168 | Racial Disparities Affecting Postoperative Outcomes After Brain Tumor Resection. **2021**, 155, e665-e673 | 0 |

167	Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity. *Cells*, **2021**, 10,	7.9	0
166	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. *Neuro-Oncology*, **2021**,	1	3
165	BCL7A as a novel prognostic biomarker for glioma patients. **2021**, 19, 335		0
164	Algorithmically Deduced Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. *Cancers*, **2021**, 13,	6.6	1
163	Brain and other central nervous system tumor statistics, 2021. **2021**, 71, 381-406		44
162	Identification of a circRNA-miRNA-mRNA regulatory network for exploring novel therapeutic options for glioma. **2021**, 9, e11894		3
161	Novel Insights into the Antagonistic Effects of Losartan against Angiotensin II/AGTR1 Signaling in Glioblastoma Cells. *Cancers*, **2021**, 13,	6.6	1
160	Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. **2021**, 12, 728088		2
159	Alcohol intake and risk of glioma: results from three prospective cohort studies. **2021**, 36, 965-974		2
158	Safety and efficacy of GammaTile intracranial brachytherapy implanted during awake craniotomy. **2021**, 20, 1265-1268		2
157	Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors. **2021**, 3, vdab137		0
156	Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma. **2021**, 222, 113564		1
155	Coaxially Bioprinted Cell-Laden Tubular-Like Structure for Studying Glioma Angiogenesis. **2021**, 9, 761861		1
154	Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma.		
153	The correlation between polymorphisms in the gene and glioma susceptibility in a Chinese pediatric population. **2021**, 10, 1896-1904		
152	An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program. **2021**, 3, vdaa175		6
151	Days Gained Response Discriminates Treatment Response in Patients with Recurrent Glioblastoma Receiving Bevacizumab-based Therapies.		1
150	Photodynamic therapy of brain tumors and novel optical coherence tomography strategies forin vivomonitoring of cerebral fluid dynamics. **2020**, 13, 2030004		9

149	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. **2019**, 4,	44
148	MicroRNA-1298-3p inhibits proliferation and invasion of glioma cells by downregulating Nidogen-1. **2020**, 12, 7761-7773	9
147	RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma. **2020**, 12, 16155-16171	1
146	High expression of GPNMB indicates an unfavorable prognosis in glioma: Combination of data from the GEO and CGGA databases and validation in tissue microarray. **2020**, 20, 2356-2368	2
145	Stanniocalcin 1 is a prognostic biomarker in glioma. **2020**, 20, 2248-2256	4
144	Brain Tumor Reporting and Data System: A Pictorial Review. **2021**, 11, 175-185	
143	Systematic Review of Racial, Socioeconomic, and Insurance Status Disparities in Neurosurgical Care for Intracranial Tumors. **2021**, 158, 38-64	2
142	A Drosophila RNAi screen reveals conserved glioblastoma-related adhesion genes that regulate collective cell migration. **2021**,	
141	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. *Neuro-Oncology*, **2021**, 23, iii1-iii105	1	106
140	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.	
139	Coexistence of multiple sclerosis and brain tumors: a literature review.. **2020**, 25, 30-36	
138	Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018. **2021**, 11, 748061	6
137	Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma. **2021**, 3, vdaa171	1
136	Expression and Prognostic Role of PLOD1 in Malignant Glioma. **2020**, 13, 13285-13297	1
135	Advancement of clinical therapeutic research on glioma: A narrative review. **2020**, 3, 119	1
134	Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database. **2021**, 11, 746844	
133	AKIP1 promotes glioblastoma viability, mobility and chemoradiation resistance via regulating CXCL1 and CXCL8 mediated NF-**B** and AKT pathways. **2021**, 11, 1185-1205	3
132	The Epidemiology of Central Nervous System Tumors. **2022**, 36, 23-42	4

131	Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database.. **2021**, 12, 659921	1
130	KIAA0101 knockdown inhibits glioma progression and glycolysis by inactivating the PI3K/AKT/mTOR pathway. **2021**, 1	1
129	miRNA-338-3p inhibits glioma cell proliferation and progression by targeting MYT1L. **2021**, 179, 1-12	1
128	Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes. **2021**, 155, 215-224	5
127	Low-intensity pulsed ultrasound-generated singlet oxygen induces telomere damage leading to glioma stem cell awakening from quiescence.. **2022**, 25, 103558	1
126	EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects.. **2021**, 146, 112532	0
125	Racial/ethnic and sex differences in young adult malignant brain tumor incidence by histologic type.. **2021**, 76, 102078	1
124	In vitro and in vivo evaluation of At-labeled fibroblast activation protein inhibitor for glioma treatment.. **2022**, 55, 116600	0
123	Clinical development of IDH1 inhibitors for cancer therapy.. **2021**, 103, 102334	1
122	Sex Differences in Glioblastoma-Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999-2018.. **2022**, 11,	0
121	Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management.. **2022**, 29, 360-376	3
120	MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines.. **2022**, 11,	1
119	RPP25 as a Prognostic-Related Biomarker That Correlates With Tumor Metabolism in Glioblastoma.. **2021**, 11, 714904	0
118	Progress and possibilities for patient-derived iPSCs and genetically engineered stem cells in cancer modeling and targeted therapies. **2022**, 247-288	
117	A Population-Based Study of Treatment and Survival in Older Glioma Patients.	1
116	Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?. **2022**, 22, 32	1
115	Development and Validation of a Personalized Prognostic Prediction Model for Patients With Spinal Cord Astrocytoma.. **2021**, 8, 802471	1
114	First clinical investigation of near-infrared window IIa/IIb fluorescence imaging for precise surgical resection of gliomas.. **2022**, PP,	1

| 113 | High myosin binding protein H expression predicts poor prognosis in glioma patients.. **2022**, 12, 1525 | 1 |

| 112 | Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma.. **2022**, 22, 53 | 0 |

| 111 | Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.. **2022**, 13, 773264 | 1 |

| 110 | Utility of Administrative Databases and Big Data on Understanding Glioma Treatment A Systematic Review. | |

| 109 | Minority children experience a higher risk of death from many central nervous system tumor types even after accounting for treatment received: A National Cancer Database analysis.. **2022**, | 0 |

| 108 | Editorial: Brain Cancers: New Perspectives and Therapies.. **2022**, 16, 857408 | 0 |

| 107 | CRISPR screening of E3 ubiquitin ligases reveals Ring Finger Protein 185 as a novel tumor suppressor in glioblastoma repressed by promoter hypermethylation and miR-587.. **2022**, 20, 96 | 1 |

| 106 | Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma.. **2022**, 17, e0245817 | 0 |

| 105 | Neuromuscular rehabilitation interventions and COVID-19 management in a case of incomplete paraplegia with neurogenic bladder, post T3-T5 ependymoma. **2022**, 479 | |

| 104 | Combining Radiology and Pathology for Automatic Glioma Classification.. **2022**, 10, 841958 | 0 |

| 103 | Inherited genetics of adult diffuse glioma and polygenic risk scores - a review. | |

| 102 | Can inflammasomes promote the pathophysiology of glioblastoma multiforme? A view about the potential of the anti-inflammasome therapy as pharmacological target.. **2022**, 103641 | 0 |

| 101 | Glioblastoma Multiforme With CDKN2A, Loss of PTEN and EGFR Amplification, and Diffuse Distant Organ Metastasis Treated With Six Lines of Therapy: A Case Report and Literature Review.. *Cureus*, **2022**, 14, e23796 | 1.2 | |

| 100 | Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.. *Neuro-Oncology*, **2022**, | 1 | 0 |

| 99 | Global variation in young adult central nervous system tumor incidence by region, age, and sex from 1988 to 2012.. **2022**, 78, 102151 | 0 |

| 98 | Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma.. **2021**, 9, 1804 | 0 |

| 97 | A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier penetrant nanoparticles. | 1 |

| 96 | Tracking the Corticospinal Tract in Patients With High-Grade Glioma: Clinical Evaluation of Multi-Level Fiber Tracking and Comparison to Conventional Deterministic Approaches.. **2021**, 11, 761169 | 3 |

95	The ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein.. **2021**, 12, 12636-12645		1
94	Microrchidia family CW-type zinc finger 2 promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N-myc downstream regulated gene 1 promoter.. **2022**, 49,		0
93	Identification and isolation of slow-cycling glioma stem cells. **2022**,		
92	Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis.. *Acta Neurochirurgica*, **2022**, 1	3	1
91	Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.. *Neuro-Oncology*, **2022**,	1	0
90	Image_1.JPEG. **2020**,		
89	Image_2.JPEG. **2020**,		
88	Data_Sheet_1.docx. **2020**,		
87	Table_2.XLSX. **2020**,		
86	Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas.. *Clinical Cancer Research*, **2022**,	12.9	2
85	Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management.. *Neurological Sciences*, **2022**,	3.5	
84	Updates in IDH-Wildtype Glioblastoma. *Neurotherapeutics*,	6.4	1
83	The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients. *Neurological Sciences*,	3.5	1
82	Sugiol Suppresses the Proliferation of Human U87 Glioma Cells via Induction of Apoptosis and Cell Cycle Arrest. *Evidence-based Complementary and Alternative Medicine*, **2022**, 2022, 1-5	2.3	4
81	Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*, **2022**,	2.8	1
80	Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report. *Brain Tumor Pathology*,	3.2	
79	A predictive microfluidic model of human glioblastoma to assess trafficking of bloodBrain barrier-penetrant nanoparticles. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	4
78	The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions. *Clinical and Translational Oncology*,	3.6	0

77	GFAP Alternative Splicing and the Relevance for Disease □A Focus on Diffuse Gliomas. *ASN Neuro*, **2022**, 14, 175909142211020	5.3	0
76	The role of A-kinase interacting protein 1 in regulating progression and stemness as well as indicating the prognosis in glioblastoma. *Translational Oncology*, **2022**, 22, 101463	4.9	
75	Expression and Prognostic Role of Glia Maturation Factor-□in Gliomas. *Frontiers in Molecular Neuroscience*, 15,	6.1	
74	Dicer deficiency impairs proliferation but potentiates anti-tumoral effect of macrophages in glioblastoma. *Oncogene*,	9.2	
73	Racial and ethnic disparities in brain tumour survival by age group and tumour type. *British Journal of Neurosurgery*, 1-7	1	
72	Human Immunodeficiency Virus in Adults Undergoing Surgery for Brain Tumors. *Cureus*, **2022**,	1.2	
71	Neural Regulation of Cancer: Cancer-Induced Remodeling of the Central Nervous System. *Advanced Biology*, 2200047		
70	Role of Circular RNA in Brain Tumor Development. *Cells*, **2022**, 11, 2130	7.9	2
69	Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics. *Neuro-Oncology*,	1	0
68	Overexpression of NNMT in Glioma Aggravates Tumor Cell Progression: An Emerging Therapeutic Target. *Cancers*, **2022**, 14, 3538	6.6	1
67	Knockdown of PHLDA2 promotes apoptosis and autophagy of glioma cells through the AKT/mTOR pathway. 1-7		
66	Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.		3
65	Far-Red Fluorescent Murine Glioma Model for Accurate Assessment of Brain Tumor Progression. **2022**, 14, 3822		0
64	Methodological Approaches to Ketogenic Dietary Treatments in Glioma Patients from a Nutritional Point of View. 1-11		0
63	Non-invasive tumor probability maps developed using autopsy tissue identify novel areas of tumor beyond the imaging-defined margin.		
62	Socioeconomic deprivation and survival outcomes in primary central nervous system lymphomas. 12,		0
61	Depression and Quality of Life in Patients with Gliomas: A Narrative Review. **2022**, 11, 4811		2
60	Modern advances in molecular and cellular biology in the treatment of glioblastoma. **2022**, 11, 66		0

59   Neuroimaging issues in assessing glioma response to brain tumour therapy. **2022**, 809-819   0

58   TRAF4 Promotes the Proliferation of Glioblastoma by Stabilizing SETDB1 to Activate the AKT Pathway. **2022**, 23, 10161   0

57   A pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in glioma.   0

56   Mathematical modelling of the dynamics of image-informed tumor habitats in a murine model of glioma.   0

55   Patterns of Care and Survival of Chinese Glioblastoma Patients in the Temozolomide Era: A Hong Kong Population-Level Analysis over a 14-year Period.   0

54   Racial disparities in pediatric malignant glioma management: current state of affairs in the United States.   0

53   Abietane diterpenoids from Phlegmariurus carinatus and their biological activities. **2022**, 113457   0

52   Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children. **2022**, 18, e1010388   0

51   Overcoming the bloodBrain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. **2022**, 20,   4

50   N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas. 553-569   1

49   CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 20152019. **2022**, 24, v1-v95   14

48   Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. **2022**, 11, 5855   0

47   Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.   0

46   A prognostic cuproptosis gene signature predicts immune function and chemotherapy response in gliomas.   0

45   Comparative analysis of the prognosis of external beam radiation therapy (EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a SEER population-based study. **2022**, 17,   0

44   A national stratification of the global macroeconomic burden of central nervous system cancer. **2022**, 1-9   0

43   Medical Device Advances in the Treatment of Glioblastoma. **2022**, 14, 5341   1

42   Potential Therapeutic Effects of Thiazolidinedione on Malignant Glioma. **2022**, 23, 13510   1

41	Evaluating the Utilization of Ethylenediaminetetraacetic Acid as a Treatment Supplement for Gliomas. **2022**,	0
40	Photodynamic Opening of the Blood―Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors. **2022**, 14, 2612	1
39	Mortality of central nervous system tumors in pediatric patients of Brazil from 1979 to 2019.	0
38	Cost Matrix of Molecular Pathology in Glioma―Towards AI-Driven Rational Molecular Testing and Precision Care for the Future. **2022**, 10, 3029	0
37	Laser interstitial thermal therapy for the treatment of primary and metastatic brain tumors: a systematic review and meta-analysis. **2022**,	0
36	Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel. **2022**, 25,	0
35	Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases.	1
34	Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model. 13,	0
33	CDC42― promising target of glioma treatment related to Treg cell proliferation.	0
32	The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification). **2023**, 23,	0
31	Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research. **2023**, 24, 348	0
30	Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas.	0
29	Prognostic evaluation of patients with glioblastoma using a new score prediction model. **2023**,	0
28	The clinical progression of patients with glioblastoma. **2023**, 32, 101756	0
27	Natural Killer Cell-Based Immunotherapy against Glioblastoma. **2023**, 24, 2111	0
26	Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy. **2023**, 24, 2835	0
25	Low-Level Laser Treatment Induces the Blood-Brain Barrier Opening and the Brain Drainage System Activation: Delivery of Liposomes into Mouse Glioblastoma. **2023**, 15, 567	0
24	Prognostic RNA-editing signature predicts immune functions and therapy responses in gliomas. 14,	0

23	Reconstruction of the Corticospinal Tract in Patients with Motor-Eloquent High-Grade Gliomas Using Multilevel Fiber Tractography Combined with Functional Motor Cortex Mapping. **2023**, 44, 283-290	0
22	PTPN18 Serves as a Potential Oncogene for Glioblastoma by Enhancing Immune Suppression. **2023**, 2023, 1-21	0
21	Frailty as a predictor of neurosurgical outcomes in brain tumor patients: A systematic review and meta-analysis. 14,	0
20	Mathematical modelling of the dynamics of image-informed tumor habitats in a murine model of glioma. **2023**, 13,	1
19	National Brain Tumour Registry of China (NBTRC) statistical report of primary brain tumours diagnosed in China in years 2019–2020. **2023**, 100715	0
18	Update for astrocytomas: medical and surgical management considerations. 1-26	0
17	The Influence of Ethnicity on Survival from Malignant Primary Brain Tumours in England: A Population-Based Cohort Study. **2023**, 15, 1464	0
16	Epithelial–Mesenchymal Transition Expression Profile Stratifies Human Glioma into Two Distinct Tumor-Immune Subtypes. **2023**, 13, 447	0
15	Gold nanoparticles enhances radiosensitivity in glioma cells by inhibiting TRAF6/NF-κB induced CCL2 expression. **2023**, 9, e14362	0
14	Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. **2023**, 12, 843	0
13	OLFML3, as a potential predictor of prognosis and therapeutic target for glioma, is closely related to immune cell infiltration. 20220052	0
12	The Current State of Adult Glial Tumor Patients' Care in Kazakhstan: Challenges in Diagnosis and Patterns in Survival Outcomes. **2023**, 11, 886	0
11	Area-level socioeconomic status is positively correlated with glioblastoma incidence and prognosis in the United States. 13,	0
10	Transcranial photosensitiser-free laser treatment of glioblastoma in rat brain.	0
9	Development of a Synthetic, Injectable Hydrogel to Capture Residual Glioblastoma and Glioblastoma Stem-Like Cells with CXCL12-Mediated Chemotaxis.	0
8	Lead Optimization of Androgen Receptor-HSP27 Disrupting Agents in Glioblastoma.	0
7	Potassium Ion Channels in Glioma: From Basic Knowledge into Therapeutic Applications. **2023**, 13, 434	0
6	Diffuse Isocitrate Dehydrogenase–Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis. **2023**, Publish Ahead of Print,	0

5	Development and Validation of Nomogram Model to Predict Cancer-Specific Survival and Overall Survival in Adult Patients with Malignant Glioma: A Population-Based Analysis.	0
4	????????????????????? ??.	0
3	Fractionated Stereotactic Re-Irradiation for recurrent glioblastoma: a systematic review and meta-analysis. **2023**, 107728	0
2	Predictive models and survival analysis of postoperative mental health disturbances in adult glioma patients. 13,	0
1	How to handle brain tumors after esophagectomy with curative intent: A single center 20-year experience. **2023**,	0